Chalante is one of the twelve companies selected to present at the Animal Health Investment Europe Emerging Company Showcase on Tuesday 20th of February 2018. More information is available on the 2018 Animal Health Investment Europe webpage.
For the past year or so, Acidophil has been developing Chalante, based in Cambridge UK. Over this time, Chalante has been supported by a combination of seed investment from Acidophil and Innovate UK grants. We are currently seeking additional investors to join Acidophil in a Series A round, to accelerate Chalante’s programs and reach key value inflection points.
Agilent Technologies Inc. (NYSE: A) (“Agilent”) today announced that it has acquired the molecular and sample barcoding patent portfolios of Population Genetics Technologies (“Population Genetics”). Founded in 2005, Population Genetics was formed to commercialize the intellectual property portfolio of Nobel Laureate Sydney Brenner focused on high sensitivity and high specificity Next Generation Sequencing (“NGS”) detection. In 2015, Population Genetics became an IP holding entity with over 30 patents. Financial terms of the purchase were not disclosed.
AgriMetis, the crop protection spin-off from healthcare innovation firm Acidophil, has raised $23.5 million in Series B funding in an oversubscribed round led by Anterra Capital.
From beneficial microbes to drones, the field of agriculture is a fertile one for start-ups. But young businesses usually avoid working on chemical crop protection. Long, costly development timelines for novel products make it a tough row to hoe. That makes AgriMetis a standout. The firm plans to thrive by developing herbicides, insecticides, and fungicides with new modes of action.
BioSyntha Technology Ltd and ZuvaChem LLC announced this week that they have merged, bringing enhanced focus and resources to commercialise the microbial production of industrial chemicals from inexpensive renewable feedstocks such as syngas and methanol. The financing secured in conjunction with this merger supports the company’s lead program for the production of 1,3-butadiene. The Company will also seek further collaborations with industrial partners to develop and commercialise its novel bio-route to 1,3-butanediol and associated derivatives.
Arginetix, Inc. and Immune Control Inc. today announced their merger to form Corridor Pharmaceuticals, Inc., which will develop novel treatments for vascular diseases with an initial focus on pulmonary arterial hypertension (PAH). Corridor will develop treatments based on the first-in-class arginase inhibition platform developed by Arginetix, and Immune Control’s serotonin antagonist technology. Gary Lessing, formerly the CEO of Arginetix, will serve as CEO of Corridor, and Stephen Roth, Ph.D., formerly CEO of Immune Control, will serve as executive vice chairman of the board of directors.